News

News

November 1, 2018

Interview Follicum: The results are very exciting and motivate us to start a topical study

Yesterday, Follicum presented top-line results from the First-In-Man scalp study with FOL-005 for stimulation of hair growth. The results confirm that the treatment is well tolerated and show that FOL-005 has the capacity to stimulate hair growth at optimal dosage. BioStock contacted the company’s CEO, Jan Alenfall, for further comments about the study and the […]

November 1, 2018

Follicum presents diabetes research at Bio-Europe in Copenhagen

Follicum AB (“Follicum” or the Company”) today announces that the Company will present results from their diabetes research during the session ”Is the ecosystem of translational metabolic research in greater Copenhagen sustaining a competitive biotech industry?” November 7. The meeting starts with a panel debate lead by Thomas Landh from Novo Nordisk followed by a […]

October 3, 2018

Follicum AB on schedule to present top-line results from the phase IIa study with FOL-005 for hair growth at the end of October 2018

Follicum AB (“Follicum”) reported on August 28, 2018 that all patients in the phase IIa study with FOL-005 for hair growth had completed their treatment. Today Follicum, in according with the company’s communicated time lines, announced it expects to present top-line results from the Phase IIa study by the end of October 2018. Follicum’s Phase […]

October 2, 2018

“Positive data could result in fewer cases of heart attack and stroke in diabetic patients in the future”*

Follicum develops peptide-based medication for hair growth stimulation and diabetes. The combination might at first seem strange, but the company justifies the grouping through the biological connection of the indications involved. BioStock has spoken to professor Anna Hultgårdh, one of the company founders, who clarifies how the two indications are connected and how synergies arise […]

September 27, 2018

Treating hair loss and diabetes

Follicum is developing an anti-diabetic treatment while simultaneously providing treatment for hair loss. At first glance this may seem like an odd combination in a development portfolio, but in fact the two indications are like two beads on a string of pearls. The two endogenously derived peptides FOL-005 and FOL-014 are currently being developed by […]

September 6, 2018

Presentation of Follicum at LSX Nordic Congress 30 August 2018

Follicum’s CEO Jan Alenfall presented the company at LSX Nordic Congress in Stockholm 30 August 2018. See the presentation For further information, please contact: Jan Alenfall – CEO, Follicum AB Telephone: +46 (0)46 – 19 21 97 Email: info@follicum.com About Follicum AB Follicum is a biotech company focused on the discovery and development of peptide-based […]

September 3, 2018

Interview with Jonas Edelswärd, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum? I have more than 25 years of experience from various positions in high-tech start-up companies, particularly from the innovation environments around Lund University and Malmö University, Ideon Innovation and MINC incubator. I have also worked with more mature companies, such as CEO for […]

August 20, 2018

Interview with Alejandra Mørk, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum? I have worked with drug development in Pharma for 18 years, in areas of clinical development, regulatory affairs, project management and was my last years in pharma overall responsible for Drug Development in Nycomed. During that period, I was also very engaged in […]

June 26, 2018

Summer Greetings from Follicum

The first part of 2018 has been a period of intensive development for Follicum. Reaching several milestones, we included the first patients in the new Phase II study for stimulation of hair growth, while simultaneously working to generate new preclinical data to strengthen the diabetes patent where we also included a new peptide class. Patient recruitment in the hair study has exceeded expectations and all patients were included in early June, meaning the project is running according to plan. Patients are treated thrice weekly for three months, which means that we plan to report the results during the last quarter of this year. We have also been busy developing and evaluating three different types of formulations of FOL-005 for application to the skin. Recently, we have announced that we chose a formulation that matches the requirements for stability and transport of FOL-005 to the hair follicle. Additionally, this formulation has the most appealing cosmetic properties.

June 20, 2018

Interview with Gun-Britt Fransson, new Chairman of the Board in Follicum

What is your background and what have you done before joining Follicum? I have a biomedical education with a PhD in Nutrition and have as long as I can remember been convinced that new research can make the world a better place. This has been reflected in my over 30-year career in research-leading positions in […]